Latest / Community Health Media
Dr. Mark Pegram & Dr. Fengting Yan - Destiny-Breast09: Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer?
Recorded at the 2025 San Antonio Breast Cancer Symposium, Dr. Mark Pegram (Stanford University) and Dr. Fengting Yan (Swedish Cancer Institute) break down the data that may redefine first-line treatment for HER2-positive metastatic breast cancer.
This expert discussion dives deep into DESTINY-Breast09, exploring unprecedented progression-free survival results with T-DXd + pertuzumab, implications for brain metastases, response durability, toxicity management, and whether the long-standing CLEOPATRA regimen is finally being challenged.
From induction–maintenance strategies to personalized…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.